Health Care & Life Sciences » Biotechnology | Dynavax Technologies Corp.

Dynavax Technologies Corp. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
11,251.00
11,032.00
4,050.00
11,043.00
327.00
8,198
SG&A Expense
76,412.00
100,939.00
106,037.00
117,035.00
86,334.00
133,308
EBIT
66,488.00
91,311.00
103,352.00
108,249.00
90,445.00
150,527
Unusual Expense
-
-
3,392.00
2,458.00
5,560.00
2,792
Non Operating Income/Expense
348.00
433.00
317.00
2,492.00
486.00
70
Interest Expense
-
35.00
572.00
-
-
9,338
Pretax Income
66,720.00
90,722.00
106,794.00
112,444.00
95,154.00
158,899
Consolidated Net Income
66,720.00
90,722.00
106,794.00
112,444.00
95,154.00
158,899
Net Income
66,720.00
90,722.00
106,794.00
112,444.00
95,154.00
158,899
Net Income After Extraordinaries
66,720.00
90,722.00
106,794.00
112,444.00
95,154.00
158,899
Net Income Available to Common
75,189.00
90,722.00
106,794.00
112,444.00
95,154.00
158,899
EPS (Basic)
3.80
3.45
3.25
2.92
1.81
2.55
Basic Shares Outstanding
19,627.50
26,289.00
32,881.00
38,506.00
52,613.00
62,362
EPS (Diluted)
3.83
3.45
3.25
2.92
1.81
2.55
Diluted Shares Outstanding
19,627.50
26,289.00
32,881.00
38,506.00
52,613.00
62,362
EBITDA
65,161.00
89,907.00
101,987.00
105,992.00
86,007.00
136,044
Non-Operating Interest Income
116.00
191.00
205.00
755.00
1,337.00
3,828
Preferred Dividends
8,469.00
-
-
-
-
-

About Dynavax Technologies

View Profile
Address
2929 Seventh Street
Berkeley California 94710
United States
Employees -
Website http://www.dynavax.com
Updated 07/08/2019
Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the development and discovery of novel vaccines and immuno-oncology therapeutics. It focuses on leveraging the body's innate and adaptive immune responses through toll-like receptor stimulation. It offers products for vaccines, cancer immunotherapy, and immune-mediated diseases.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.